IL18 interleukin 18
ENSG00000150782 · protein coding · Open Targets profile
Pro-inflammatory cytokine primarily involved in epithelial barrier repair, polarized T-helper 1 (Th1) cell and natural killer (NK) cell immune responses (PubMed:10653850). Upon binding to IL18R1 and IL18RAP, forms a signaling ternary complex which activates NF-kappa-B, triggering synthesis of inflammatory mediators (PubMed:14528293, PubMed:25500532, PubMed:37993714). Synergizes with IL12/interleukin-12 to induce IFNG synthesis from T-helper 1 (Th1) cells and natural killer (NK) cells (PubMed:10653850). Involved in transduction of inflammation downstream of pyroptosis: its mature form is specifically released in the extracellular milieu by passing through the gasdermin-D (GSDMD) pore (PubMed:33883744). {ECO:0000269|PubMed:10653850, ECO:0000269|PubMed:14528293, ECO:0000269|PubMed:25500532, ECO:0000269|PubMed:33883744, ECO:0000269|PubMed:37993714}.
Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.
Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Antibody
- Advanced Clinical, UniProt loc high conf, GO CC high conf
- PROTAC
- Database Ubiquitination, Half-life Data, Small Molecule Binder
- Other modalities
- Advanced Clinical
gnomAD loss of function constraint: o/e 0.5616700053215027 (upper bound 1.0133999586105347). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
Principal investigators and study chairs on 11 registry trials, updated in the last three years, of the most advanced drugs against IL18 (tadekinig alfa, camoteskimab, GSK-1070806), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.
- Ed M BehrensChildren Hospital of Philadelphia · 1 of 1 trials Phase 2+
- Eduard BehrensChildren Hospital of Philadelphia · 1 of 1 trials Phase 2+
Registry trials of tadekinig alfa, camoteskimab, GSK-1070806 updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 4 of 11 have all sites in one country.
Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. Source: ClinicalTrials.gov, fetched live.
4 trials of drugs against IL18 were stopped early
Terminated, withdrawn and suspended interventional trials of tadekinig alfa, camoteskimab, GSK-1070806, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 4 most recent of 4.
- terminated · 2026-06-16 · GlaxoSmithKline · matched by the registry's drug synonyms“Sponsor decision to early terminate the study following the termination of the parent study (NCT05999799), which met pre-defined futility criterion for efficacy. No safety concerns were identified.”
- terminated · 2026-06-03 · GlaxoSmithKline · matched by the registry's drug synonyms“Sponsor decision to early terminate the study based on the pre-defined futility criterion for efficacy. No safety concerns were identified.”
- terminated · 2023-08-23 · Apollo Therapeutics Ltd · Camoteskimab (CERC-007, AVTX-007, AEVI-007)“Sponsor discretion”
- terminated · 2019-06-26 · GlaxoSmithKline · matched by the registry's drug synonyms“Lack of efficacy”
Paediatric incentives and obligations for IL18's drugs
For tadekinig alfa, camoteskimab, GSK-1070806: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: no · IL18 is not on the listRule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: no · No EMA paediatric investigation plan decision names tadekinig alfa, camoteskimab, gsk-1070806Rule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA data download (dated snapshot), 2026-11-11
- EU orphan designation: yes · EU/3/16/1763 positive 14 Oct 2016: Treatment of haemophagocytic lymphohistiocytosisRule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA EU/3/16/1763, 2026-11-11
- Authorised in the EU: no · EMA lists no centrally authorised medicine of tadekinig alfa, camoteskimab, gsk-1070806Rule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA data download (dated snapshot), 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of tadekinig alfa, camoteskimab, gsk-1070806Rule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-12
- Registered studies open to children: yes · 3 interventional studies of tadekinig alfa, camoteskimab, gsk-1070806 include patients under 18; 0 are recruiting, not yet recruiting or activeRule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-12
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 3 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.
| Drug | Type | Highest stage | Indications | Source records |
|---|---|---|---|---|
| TADEKINIG ALFA | Unknown | phase 3 | hemophagocytic syndrome, adult-onset Still disease, B-cell non-Hodgkin lymphoma, rheumatoid arthritis | Open Targets · ChEMBL |
| CAMOTESKIMAB | Antibody | phase 2 | atopic eczema, chronic obstructive pulmonary disease, plasma cell myeloma, adult-onset Still disease, neoplasm | Open Targets · ChEMBL |
| GSK-1070806 | Unknown | phase 2 | type 2 diabetes mellitus, Behcet disease, atopic eczema, Crohn disease | Open Targets · ChEMBL |